Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.46 |
| ▸ | CES1 | P23141 | 5/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PPARD | Q03181 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6857754 | 0.97 | CES2 (0.48) | CES2CES1FAAHGPR84PPARG | |
| SCHEMBL7057112 | 0.97 | CES2 (0.48) | CES2CES1FAAHGPR84PPARG | |
| SCHEMBL5704388 | 0.89 | CES2 (0.42) | CES2CES1AKR1B1FAAHGPR84 | |
| SCHEMBL7057813 | 0.87 | CES1 (0.44) | CES2CES1FAAHGPR84PPARG | |
| SCHEMBL15158037 | 0.87 | CES1 (0.44) | CES2CES1FAAHGPR84PPARG | |
| SCHEMBL9782912 | 0.86 | CES1 (0.40) | CES2CES1AKR1B1FAAHTSHR | |
| SCHEMBL10457444 | 0.78 | CES2 (0.37) | CES2CES1TSHRALDH1A1 | |
| SCHEMBL19895687 | 0.77 | CES2 (0.46) | CES2CES1AKR1B1FAAHGPR84 | |
| SCHEMBL19326566 | 0.76 | CES2 (0.40) | CES2CES1AKR1B1FAAHGPR84 | |
| SCHEMBL3802950 | 0.74 | FAAH (0.58) | CES2CES1AKR1B1FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820460-A1 | METHODS FOR REVERSING HIV LATENCY USING BAF COMPLEX MODULATING COMPOUNDS | The Board of Trustees of the Leland Stanford Junior University (US) | 2021-05-19 | — | — | EP | disclosed |
| US-7955718-B2 | Organic EL element and process for manufacture of organic EL element | TDK CORPORATION (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20070066608-A1 | Novel indole derivatives with an improved antipsychotic activity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | INNATE PHARMA, S.A.S. (FR) | 2006-08-31 | — | — | US | disclosed |
| US-20060115681-A1 | Organic EL element and process for manufacture of organic EL element | TDK CORPORATION (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-0532642-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| EP-0532642-A1 | SUBSTITUTED GUANIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF | STATE OF OREGON, acting through OREGON STATE BOARD OF HIGHER EDUCATION, acting for OREGON HEALTH SC. UNIV. AND UNIV. OF OREGON (US) | 1993-03-24 | — | — | EP | disclosed |
| WO-1991018868-A1 | SUBSTITUTED GUANIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF | STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION, acting for and onbehalf of the OREGON HEALTH SCIENCES UNIVERSITY (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066608-A1 | Novel indole derivatives with an improved antipsychotic activity | HTR1A, TPH1, HTR1D | CES2 3796/4885CES1 3066/4885AKR1B1 717/4885 |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | IFNG, IL2, ICOS | CES2 4083/4885CES1 3478/4885AKR1B1 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.